The Management of Cytokine Storm in COVID-19

Cleopas Martin Rumende, Erwin C Susanto, Truely P Sitorus


Cytokine storm in COVID-19 infection is an excessive immune response to external stimuli where the pathogenesis is complex. The disease progresses rapidly and the mortality is high. Certain evidence shows that the severe deterioration of some patients has been closely related to the strong upregulation of cytokine production in SARS-Co-V2 induced pneumonia with an associated cytokine storm syndrome. Identification of existing approaved therapy with proven safety profile to treat hyperinflammation is critical unmet need in order to reduce COVID-19 associated mortality. To date, no specific therapeutic drugs are available to treat COVID-19 infection. Preliminary studies have shown that immune-modulatory or immune suppressive treatments might be considered as treatment choices for COVID-19, particularly in severe disease. This article review the pathogenesis and treatment strategies of COVID-19 virus-induced inflammatory storm in attempt to provide valuable medication guidance for clinical treatment.


cytokine storm; hyperinflammation; COVID-19


Clinical management of COVID-19. Interim Guidance. Geneva : World Health Organization; 2020.

Qing Ye, Bili Wang, Jianhua Mao. The pathogenesis and treatment of the cytokine storm in COVID-19. J Infect Dis. 2020.

Mousavizadeh L, Ghasemi S, Genotype and phenotype of COVID-19: Their roles in pathogenesis. J Microbiol Immunol Infect. 2020.

Singh VK, Mishra A, Singh S, Kumar P, Singh M, Jangannath C, Khan A. Emerging prevention and treatment strategies to control COVID-19. Pathogen. 2020;9;2-16.

Tufan A, Guler AA, Cerinic MM. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk J Med Sci. 2020;50:620-30.

Felsenstein S, Herbert J, McNamara P, Hedrich CM. COVID-19: Immunology and treatment options. Clin Immunol. 2020.

Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J Hearth Lung Transplant. 2020;39:405-7.

COVID-19: Pathogenesis, cytokine storm and therapeutic potensial of interferons. Cytokine Growth Factor Rev. 2020.

Roche AG. Cytokines release syndrome, reviewing a new entity in the intensive care unit. Med Intensiva. 2019;43 (8):480-8.

Gupta KK, Khan MA, Singh SK. Constitutive inflammatory cytokines storm: A major threat to human health. J Interfer Cytokine Res. 2020;40 (1):1-5.

Instiaty, Darmayani I G A P. Marzuki JE, et al. Antiviral treatment of COVID-19: clinical pharmacology narrative review. Med J Indones. 2020.

Sanders JM, Monogue ML, JodlowskiTZ, Cutrell JB. Pharmacologic treatment for Coronavirus disease 2019 (COVID-19). JAMA. 2020;323:1824-36.

Delang L, Neyts J. Medical treatment options for COVID-19. Eur Heart J: Acute Cardiovas Care. 2020; 9: 209-14.

Murthy H. Cytokines release syndrome: Current perspectives. Immuno Targers Ther. 2019;8:43-52.

Iannaccone G, Scacciavillani R, Del Buono MG, et al. Weathering the cytokine storm in COVID-19: Therapeutic implication. Cardiorenal Med. Doi: 10.1159/000509483.

Cao W. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with Coronavirus disesase is 2019. Infect Dis Soc Am. 2020.

Xiaosheng Liu, Wei Cao, Taisheng Li. High-dose intravenous immunoglobulins in the treatment of sebere acute viral pneumonia: the known mechanism and clinical effect. Frontiers Immunology. Doi: 10.3389/fimm.2020.01660.

Chen L. Convalescent plasma as a potential therapy for COVID-19. Lancet. 2020; 0: 98-400.

Shen C. Treatment of 5 Critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020.

Al-Anazi KA, Al-Alnazi WK, Al-Jasser AM. Update on COVID-19 infections and the promising role of mesenchymal stem cell therapies in their management. 2020.

Full Text: PDF


  • There are currently no refbacks.